
open access
메뉴
E-ISSN : 2671-6771
This review chronicles the pivotal "firsts" in gene therapy, from early successes like the 1990 ex vivo trial for adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) to the profound setbacks that shaped its trajectory. Tragic events, including leukemia from insertional mutagenesis in SCID-X1 trials and the death of Jesse Gelsinger from a catastrophic immune response, forced a critical re-evaluation of vector safety and regulatory oversight. This introspection led to the development of safer adeno-associated virus (AAV) vectors and the landmark success of in vivo therapy with Luxturna for Leber's congenital amaurosis. The path to commercial viability saw the failure of Glybera contrasted with the blockbuster success of Zolgensma for spinal muscular atrophy, paving the way for the current era of CRISPR-based gene editing with the approval of Casgevy. This history reveals a field matured through adversity, now delivering transformative therapies while still facing critical challenges in cost, immunogenicity, and long-term durability.
Silver–Russell syndrome (SRS) is a rare imprinting disorder characterized by prenatal and postnatal growth retardation, relative macrocephaly, prominent forehead, body asymmetry, and feeding difficulties. The estimated incidence ranges from 1 in 30,000 to 1 in 100,000 live births. Diagnosis is primarily clinical, supported by the Netchine–Harbison Clinical Scoring System (NH-CSS), while molecular confirmation is achieved in approximately 60% of cases. The two major genetic mechanisms are loss of methylation (LOM) at chromosome 11p15 and maternal uniparental disomy for chromosome 7 (upd(7)mat); rarer causes include abnormalities involving chromosomes 14q32, 20, and 16, or mutations in CDKN1C or IGF2. Management focuses on optimizing nutrition, preventing hypoglycemia, and addressing growth failure. Growth hormone (GH) therapy effectively improves height, body composition, and appetite in most patients, though partial IGF-1 resistance may occur, particularly in 11p15 LOM. Puberty often begins early and progresses rapidly, contributing to compromised final height; combined GH and GnRH analogue therapy may be beneficial in selected cases. Long-term follow-up is required to monitor metabolic outcomes and support individualized care based on molecular subtype. A multidisciplinary approach remains essential to address the complex endocrine, nutritional, and developmental challenges of SRS throughout childhood and adolescence.
Lipoproteins and apolipoproteins are essential macromolecules that maintain systemic lipid homeostasis and cellular energy balance by transporting lipids through plasma and interstitial fluids. Structurally, lipoproteins consist of hydrophobic lipid cores surrounded by amphipathic apolipoproteins, which determine their metabolic fate, receptor interactions, and physiological functions. Among apolipoproteins, apolipoprotein E (APOE) plays critical roles in lipid transport, nerve repair, and immune regulation. APOE encoded by APOE gene (OMIM*107741) exists in three common isoforms (APOE2, APOE3, and APOE4), which differ by cysteine/arginine substitutions at residues 112 and 158. These subtle structural changes profoundly alter receptor binding affinity, lipidation efficiency, and protein stability, resulting in distinct metabolic and pathological outcomes. In particular, APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). APOE4 promotes amyloid-β (Aβ) aggregation, impairs Aβ clearance, enhances tau hyperphosphorylation, and triggers neuroinflammatory signaling. APOE-mimetic peptides, designed to replicate key functional domains of the native protein, exhibit neuroprotective, anti-inflammatory, and lipid-modulatory effects in preclinical models of AD, stroke, and atherosclerosis. Concurrently, advances in APOE genotyping are expanding clinical applications in AD risk prediction, lipid-lowering therapy, and personalized prevention. Understanding the molecular mechanisms and clinical relevance of the APOE gene remains essential for translating genetic insights into therapeutic and diagnostic innovation across metabolic and neurodegenerative diseases. This review highlights the APOE gene as a pivotal link between lipid metabolism and neurodegeneration. Integration of recent advances in its structural variants, disease mechanisms, therapeutic modulation, and clinical genotyping underscores the importance of APOE as both a biomarker and a therapeutic target.
Congenital hyperinsulinism (CHI) is the leading cause of severe and persistent hypoglycemia in infants and children. Hyperinsulinemic hypoglycemia (HH) represents a clinically and genetically heterogeneous disorder, manifesting as transient forms related to perinatal stress or persistent forms caused by molecular defects in the genes regulating insulin secretion from pancreatic β-cell. Pathogenic variants in the KATP channel genes (ABCC8, KCNJ11) are the most frequent causes, although variants in other channels/transporter, metabolic enzymes, and transcription factors have also been reported. Syndromic forms associated multisystemic disorders also recognized. Prompt recognition of hypoglycemia, determination of its underlying etiology, and appropriate management are crucial to prevent irreversible neurodevelopmental impairment.
Neuromuscular diseases (NMDs) comprise a heterogeneous spectrum of inherited and acquired disorders affecting anterior horn cells, peripheral nerves, neuromuscular junctions, or skeletal muscle, resulting in progressive weakness, fatigue, and functional decline. Historically, exercise was discouraged due to concerns of “overuse weakness”; however, a growing body of evidence now supports the safety and efficacy of supervised submaximal exercise as a therapeutic intervention for various NMD subtypes. Moderate-intensity aerobic and strength training improves mitochondrial biogenesis, oxidative efficiency, and preserves neuromuscular integrity through activation of the AMPK–SIRT1–PGC-1α and mTORC1–Akt signaling pathways, while promoting antioxidant and anti-inflammatory responses. Individualized exercise programs tailored to the functional status of patients and adapted to the specific metabolic and structural characteristics of certain neuromuscular diseases improve endurance, muscle strength, and quality of life without accelerating disease progression. In the era of disease-modifying therapies, the role of exercise as a complementary measure to enhance therapeutic efficacy is gaining increasing scientific and clinical importance. A multimodal, individualized approach integrating aerobic exercise, strength training, flexibility training, respiratory training, and computer-assisted interventions under clinical supervision represents the current standard of care.
Background: Kabuki syndrome (KS) is a rare disorder characterized by distinctive craniofacial features, developmental delay, short stature, and involvement of multiple organ systems. The genotype–phenotype correlation in KS remains incompletely understood. Methods: This study aimed to delineate the clinical and genetic spectrum of KS in a cohort of 27 Korean patients. Twenty-seven individuals clinically suspected of KS were evaluated at Pusan National University Children’s Hospital between March 2009 and November 2022. Comprehensive assessments were conducted across multiple systems. Statistical comparisons were performed using the Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables (IBM SPSS Statistics v21). Results: The mean age at diagnosis was 6.90 ± 6.71 years, with an average diagnostic delay of 4.56 ± 5.03 years. All patients exhibited characteristic facial features of KS. Developmental delay was observed in 92.6% of cases, followed by short stature, skeletal and ENT abnormalities (63.0% each), congenital heart disease (59.3%), ophthalmologic issues (51.9%), neurologic and urogenital involvement (48.1% each), immune dysfunction (18.5%), and hematologic malignancy (3.7%). Pathogenic or likely pathogenic KMT2D variants were identified in 23 patients (85.2%), while 4 remained genetically undiagnosed. Among the detected variants, 8 were nonsense, 7 frameshift, 6 missense, 1 splicing, and 1 duplication variant; notably, 18 (78.3%) of these were novel. Patients with pathogenic KMT2D variants were diagnosed at a significantly younger age compared to variant-negative patients (P = 0.05). Those harboring truncating variants exhibited a higher burden of multi-organ involvement compared to individuals with non-truncating variants (4.9 ± 1.4 vs. 3.0 ± 2.3; P = 0.016). Conclusion: This study broadens the clinical and molecular landscape of Kabuki syndrome in Korean patients.